- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Abcellera Biologics Inc (ABCL)
Abcellera Biologics Inc stock price live, this page displays NASDAQ ABCL stock exchange data. View the ABCL premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Abcellera Biologics Inc real time stock price chart below.
What Is the Abcellera Biologics Inc Stock Price Today?
The Abcellera Biologics Inc stock price today is 11.515.
What Is the Stock Symbol for Abcellera Biologics Inc?
The stock symbol for Abcellera Biologics Inc is "ABCL."
What Stock Exchange Does Abcellera Biologics Inc Trade On?
Abcellera Biologics Inc is listed and trades on the NASDAQ stock exchange.
Is Abcellera Biologics Inc a Good Stock to Buy?
Determining whether Abcellera Biologics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ABCL quote. (ISIN: CA00288U1066)
What Is the Abcellera Biologics Inc Stock Price Today?
The Abcellera Biologics Inc stock price today is 11.515.
What Is the Stock Symbol for Abcellera Biologics Inc?
The stock symbol for Abcellera Biologics Inc is "ABCL."
What Stock Exchange Does Abcellera Biologics Inc Trade On?
Abcellera Biologics Inc is listed and trades on the NASDAQ stock exchange.
Is Abcellera Biologics Inc a Good Stock to Buy?
Determining whether Abcellera Biologics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ABCL quote. (ISIN: CA00288U1066)
11.515
-0.055(-0.48%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.230
11.800
52 wk Range
2.745
12.150
ABCL is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
11.23011.800
52 wk Range
2.74512.150
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ABCL Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
17.125
Upside
+48.72%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in overbought territory
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Strong Buy
Analyst Ratings
9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 17.125
(+48.72% Upside)
Abcellera Biologics Inc SWOT Analysis
Innovative Platform | AbCellera's tech-enabled antibody discovery platform shows promise in drug development, validated through COVID-19 treatments and strategic partnerships. |
Financial Strength | With $1 billion in liquidity, AbCellera is well-positioned for extended operations and strategic investments, despite recent downward estimate revisions. |
Explore Partnerships | Collaborations with Biogen and Viking/ArrowMark highlight AbCellera's potential for long-term revenue growth and expanded therapeutic applications. |
Future Prospects | Analyst targets range from $7 to $12, reflecting optimism about AbCellera's internal pipeline development and manufacturing capabilities amid industry changes. |
Abcellera Biologics Inc Earnings Call Summary for Q2/2026
- AbCellera posted Q2 2026 loss of $0.18/share on revenue of $4.1M, missing estimates of $0.17 loss on $8.1M revenue; shares fell 5.4% through after-hours.
- Revenue plunged 76% YoY to $4.1M as company pivoted from external collaborations to internal drug development; net loss widened to $55M from $35M.
- Company holds $567M in cash with $675M+ total liquidity, sufficient to fund pipeline for three years; new Vertex and Jazz deals added $110M+ upfront.
- Phase II data for lead menopause drug ABCL635 expected 'very soon'; positive results would 'highly de-risk' asset and enable late-stage development.
- ABCL688 and ABCL386 to enter Phase I/II in 2027; ABCL575 Phase I data due Q4 2026; no formal guidance issued but R&D spending to remain elevated.
Last Updated: 2026-08-05, 05:50 p/m
Read Full TranscriptEarnings
Latest Release
Aug 05, 2026
EPS / Forecast
-0.18 / -0.17
Revenue / Forecast
4.1M / 8.1M
Compare ABCL to Peers and Sector
Metrics to compare | ABCL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipABCLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −22.5x | −14.0x | −0.3x | |
PEG Ratio | −8.93 | 0.01 | 0.00 | |
Price/Book | 4.1x | 2.0x | 2.6x | |
Price / LTM Sales | 56.0x | 11.4x | 3.1x | |
Upside (Analyst Target) | 29.6% | −1.4% | 47.6% | |
Fair Value Upside | Unlock | 9.2% | 5.6% | Unlock |
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Abcellera Biologics (ABCL) Stock Price Today?
The Abcellera Biologics stock price today is 11.515 USD.
What Stock Exchange Does Abcellera Biologics Trade On?
Abcellera Biologics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Abcellera Biologics?
The stock symbol for Abcellera Biologics is "ABCL."
What Is the Abcellera Biologics Market Cap?
As of today, Abcellera Biologics market cap is 3.760B USD.
What Is Abcellera Biologics's Earnings Per Share (TTM)?
The Abcellera Biologics EPS (TTM) is -0.546.
When Is the Next Abcellera Biologics Earnings Date?
Abcellera Biologics will release its next earnings report on Nov 10, 2026.
From a Technical Analysis Perspective, Is ABCL a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Abcellera Biologics Stock Split?
Abcellera Biologics has split 0 times.
How Many Employees Does Abcellera Biologics Have?
Abcellera Biologics has 562 employees.
What is the current trading status of Abcellera Biologics (ABCL)?
As of Aug 21, 2026, Abcellera Biologics (ABCL) is trading at a price of 11.515 USD, with a previous close of 11.570 USD. The stock has fluctuated within a day range of 11.230 USD to 11.800 USD, while its 52-week range spans from 2.745 USD to 12.150 USD.
What Is Abcellera Biologics (ABCL) Price Target According to Analysts?
The average 12-month price target for Abcellera Biologics is 17.125 USD, with a high estimate of 30 USD and a low estimate of 9 USD. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +48.72% Upside potential.
What Is the ABCL Premarket Price?
ABCL's last pre-market stock price is 11.600 USD. The pre-market share volume is 87,230.000, and the stock has decreased by 0.030, or 0.260%.
What Is the ABCL After Hours Price?
ABCL's last after hours stock price is 11.600 USD, the stock has decreased by 0.030, or 0.260%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.